Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Novolog Clear all
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 3, 2026, 9:43 AM EDT
Withdrawn Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes

NCT00539435
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Intravenous Insulin on cardiac disease in diabetic pts
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

NCT01045447
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
24
States / cities
Fresno, California • Waterbury, Connecticut • Boynton Beach, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional

INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

NCT00101751
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, dietary regimen
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 3, 2026, 9:43 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

NCT05946785
View directory record Official record
Conditions
Gestational Diabetes, Vascular Endothelial Function
Interventions
Acetylcholine, insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02420262
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
50
States / cities
Tuscumbia, Alabama • Anaheim, California • Bermuda Dunes, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 3, 2026, 9:43 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

NCT00505882
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide, Glargine, Lispro, Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 3, 2026, 9:43 AM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Results available

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
37
States / cities
Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 3, 2026, 9:43 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

NCT03260868
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

The Insulin-Only Bionic Pancreas Pivotal Trial

NCT04200313
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
Bionic Pancreas (BP) with Aspart or Lispro, Bionic Pancreas with Fiasp (BPFiasp), Usual Care (UC), BP Guidance Insulin Dosing
Combination Product · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
16
States / cities
Orange, California • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 3, 2026, 9:43 AM EDT
Withdrawn Not applicable Interventional

Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy

NCT02144441
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
glargine and aspart
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 3, 2026, 9:43 AM EDT
Terminated Phase 4 Interventional Results available

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

NCT03511521
View directory record Official record
Conditions
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions
NPH Insulin, glargine, Insulin Aspart
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858
View directory record Official record
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

NCT00065130
View directory record Official record
Conditions
Diabetes, Gestational Diabetes
Interventions
human insulin, insulin NPH, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

NCT01713530
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Greenbrae, California • Mission Hills, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

NCT02100475
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

NCT00791895
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart 30
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

Regular Insulin vs Rapid Insulin Delivered by V-Go

NCT03495908
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus
Interventions
VGo
Device
Lead sponsor
East Coast Institute for Research
Network
Eligibility
21 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

NCT01850615
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, basal insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Results available

Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes

NCT00590226
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Detemir + aspart insulin before meals, NPH insulin + regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Results available

Insulin Pump to Multiple Daily Injection Transition Clinical Trial

NCT03987191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiple daily ijnection using Insulin Degludec and Insulin Aspart
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 3, 2026, 9:43 AM EDT